339 related articles for article (PubMed ID: 27795518)
1. [Current treatment of refractory and relapsed multiple myeloma].
Sasaki M
Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
Kuroda J
Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
[TBL] [Abstract][Full Text] [Related]
3. [Treatment algorithms for multiple myeloma in Japan].
Ozaki S
Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
[TBL] [Abstract][Full Text] [Related]
4. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
5. [Management of multiple myeloma in the relapsed/refractory patient].
Tabayashi T
Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
[TBL] [Abstract][Full Text] [Related]
6. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Sonneveld P; De Wit E; Moreau P
Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Malard F; Harousseau JL; Mohty M
Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
9. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
10. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
11. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Relapsed/Refractory Multiple Myeloma.
Neri P; Bahlis NJ; Paba-Prada C; Richardson P
Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
[TBL] [Abstract][Full Text] [Related]
13. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines].
Ozaki S
Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524
[TBL] [Abstract][Full Text] [Related]
14. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed multiple myeloma: Evidence-based recommendations.
Durer C; Durer S; Lee S; Chakraborty R; Malik MN; Rafae A; Zar MA; Kamal A; Rosko N; Samaras C; Valent J; Chaulagain C; Anwer F
Blood Rev; 2020 Jan; 39():100616. PubMed ID: 31500848
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: from front-line to relapsed therapies.
Moreau P; Touzeau C
Am Soc Clin Oncol Educ Book; 2015; ():e504-11. PubMed ID: 25993216
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
Nishida H; Yamada T
J Oncol; 2019; 2019():6084012. PubMed ID: 31781214
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
